<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00131287</url>
  </required_header>
  <id_info>
    <org_study_id>TH-EC-05-01</org_study_id>
    <nct_id>NCT00131287</nct_id>
  </id_info>
  <brief_title>The Supplementary Effects of the Extract of Agaricus Blazei Murril on Type II Diabetes Mellitus (DM)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECbiotech Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ECbiotech Taiwan</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether the extract of the Agaricus blazei Murill
      mushroom is effective in the supplementary treatment of type II DM patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The researchers have the animal model that the extract of the Agaricus blazei Murill mushroom
      is effective in the treatment of type II DM mice conducted on 2002. The dose effects were
      also found. The researchers conducted the pilot study also showing the same effects in 2003.
      So the researchers designed this trial. The elixir of the Agaricus blazei Murill mushroom is
      popular in Taiwan for chronic diseases, such as type II DM.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction of glycated hemoglobin (HAb1C) and insulin resistance(HOMA-IR)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose, cholesterol, triglyceride, leptin, adiponectin comparisons</measure>
  </secondary_outcome>
  <enrollment>108</enrollment>
  <condition>Diabetes Mellitus, Type II</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extract of Agaricus blazei Murill</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type II DM

          -  Age 20-75 years old

          -  Treat with Gliclazide and Metformin

          -  Signed informed consent

        Exclusion Criteria:

          -  GOT/GPT &gt;80/80

          -  Creatinine &gt; 2.0

          -  Lactating or pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsu Chung-Hua, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Medicine Dep, Taipei Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chung-Hua Hsu</name>
      <address>
        <city>Taipei</city>
        <zip>886</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2005</study_first_submitted>
  <study_first_submitted_qc>August 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2005</study_first_posted>
  <last_update_submitted>January 4, 2010</last_update_submitted>
  <last_update_submitted_qc>January 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2010</last_update_posted>
  <keyword>Agaricus Blazei Murill</keyword>
  <keyword>type II DM</keyword>
  <keyword>insulin index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

